Ben Field

Dr Ben Field


Clinical Reader in Diabetes and Endocrinology
BMedSci MBBS MSc PGCertULT PhD FRCP

Biography

University roles and responsibilities

  • Caldicott Guardian

Courses I teach on

Postgraduate taught

Undergraduate

My publications

Publications

Field BCT*, Nayar R*, Kilvert A, Baxter M, Hickey J, Cummings M, Bain SC (2018). A retrospective observational study of people with Type 1 diabetes with self-reported severe hypoglycaemia reveals high level of ambulance attendance but low levels of therapy change and specialist intervention. Diabet Med 2018; 35(9): 1223-31 (*joint first author).
Godfrey RL, Clark J, Field B (2014). Bilateral adrenal haemorrhagic infarction in a patient with antiphospholipid syndrome. BMJ Case Rep. 2014 Nov 19;2014:bcr2014207050
Tan TM, Salem V, Troke RC, Alsafi A, Field BCT, De Silva A, Misra S, Baynes KCR, Donaldson M, Minnion J, Ghatei MA, Godsland IF, Bloom SR (2014). Combination of peptide YY3-36 with GLP-17-36 amide causes an increase in first-phase insulin secretion after IV glucose. J Clin Endocrinol Metab 2014; 99(11): E2317-24
Field BCT (2014). Neuroendocrinology of obesity. Br Med Bull 2014; 109: 73-82
Parker JA, McCullough KA, Field BCT, Minnion JS, Martin NM, Ghatei MA, Bloom SR (2013). Glucagon and GLP-1 inhibit food intake and increase c-fos expression in similar appetite regulating centres in the brainstem and amygdala. Int J Obes 2013; 37(10): 1391-8
Tan TM*, Field BCT*, McCullough KA, Troke RC, Chambers ES, Salem V, Gonzalez Maffe J, Baynes KCR, De Silva A, Viardot A, Alsafi A, Frost GS, Ghatei MA, Bloom SR (2013). Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia. Diabetes 2013; 62(4): 1131-8 (*joint first author)
Salem V, Hopkins TG, El-Gayar H, Zac-Varghese S, Goldstone AP, Todd JF, Dhillo W, Field BCT, Martin N, Hatfield E, Donaldson M, Palazzo F, Meeran K, Jackson J, Tan T (2012). Adrenal venous sampling as a diagnostic procedure for primary hyperaldosteronism: experience from a tertiary referral centre. Hormones 2012; 11(2): 151-9
Tan TM*, Field BCT*, Minnion JS, Cuenco-Shillito J, Chambers ES, Zac-Varghese S, Brindley CJ, Mt-Isa S, Fiorentino F, Ashby D, Ward I, Ghatei MA, Bloom SR (2012). Pharmacokinetics, adverse effects and tolerability of a novel analogue of human pancreatic polypeptide, PP 1420. Br J Clin Pharmacol 2012; 73(2): 232-9 (*joint first author)
Addison ML, Minnion JS, Shillito JC, Suzuki K, Tan TM, Field BCT, Germain-Zito N, Ghatei MA, Bloom SR, Murphy KG (2011). A role for metalloendopeptidases in the breakdown of the gut hormone, PYY3–36. Endocrinology 2011; 152(12): 4630-40
Sharma S, Radomska-Botelho Moniz A, Triantis I, Michelakis K, Trzebinski J, Azarbadegan A, Field B, Toumazou C, Eames I, Cass A (2011). An integrated silicon sensor with microfluidic chip for monitoring potassium and pH. Microfluid Nanofluid 2011; 10(5): 1119-25
Wynne K, Field BCT, Bloom SR (2010). The mechanism of action for oxyntomodulin in the regulation of obesity. Curr Opin Investig Drugs 2010; 11(10): 1151-7
Field BCT, Chaudhri OB, Bloom SR (2010). Bowels control brain: gut hormones and obesity. Nature Rev Endocrinol 2010; 6(8): 444-53
Liu Y-L, Ford H, Druce MR, Minnion JS, Field BCT, Cuenco-Shillito J, Baxter J, Murphy KG, Ghatei MA, Bloom SR (2010). Subcutaneous oxyntomodulin analogue administration reduces body weight in lean and obese rodents. Int J Obes 2010; 34(12): 1715-25
Field BCT*, Wren AM*, Peters V, Baynes KCR, Martin NM, Patterson M, Alsaraf S, Amber V, Wynne K, Ghatei MA, Bloom SR (2010). PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans. Diabetes 2010; 59(7): 1635-9 (*joint first author)
Field BCT, Chaudhri OB, Bloom SR (2009). Obesity treatment: novel peripheral targets. Br J Clin Pharmacol 2009; 68(6): 830-43
Druce MR, Minnion JS, Field BCT, Patel SR, Cuenco J, Tilby M, Murphy KG, Ghatei MA, Bloom SR (2009). Investigation of structure-activity relationships of oxyntomodulin using oxyntomodulin analogues. Endocrinology 2009; 150(4): 1712-21
Parkinson JRC, Chaudhri OB, Kuo YT, Field BCT, Herlihy AH, Dhillo WS, Ghatei MA, Bloom SR, Bell JD (2009). Differential patterns of neuronal activation in the brainstem and hypothalamus following peripheral injection of GLP-1, oxyntomodulin and lithium chloride in mice as detected by manganese-enhanced magnetic resonance imaging (MEMRI). Neuroimage 2009; 44(3): 1022-31
Chaudhri OB, Field BCT, Bloom SR (). Gastrointestinal satiety signals. Int J Obes 2008; 32 Suppl 7: S28-31
Field BCT, Wren AM, Cooke D, Bloom SR (2008). Gut hormones as potential new targets for appetite regulation and the treatment of obesity. Drugs 2008; 68(2): 147-63
Chaudhri OB, Field BCT, Bloom SR (2006). From gut to mind – hormonal satiety signals and anorexia nervosa. J Clin Endocrinol Metab 2006; 91: 797-8
Gul S, Clarke A, Field B, Thomas MP, Willenbrock F, Pinitglang S, Verma C, Thomas EW, Brocklehurst K (1997). Investigation of the electrostatic field of the papain active centre by using monoprotonated and diprotonated pyridyl (Py) disulphides as reactivity probes. Biochem Soc Trans 1997; 25(1): 91S
Royal College of Physicians (2013). Action on obesity: comprehensive care for all. Report of a working party. RCP, London, 2013 (contributed the chapter on audit, quality & research)
Field BCT, Small CJ, Bloom SR (2008). The Neurobiology of Obesity (eds. Jenni Harvey & Dominic Withers. Cambridge University Press, Cambridge, 2008 (contributed the introductory chapter)
Feather A, Field BCT, Lumley JSP & Visvanathan R (2007). Medical Finals: Short cases with structured answers, 2nd edition. Pastest, Knutsford, 2007
Feather A, Domizio P, Field BCT, Knowles, CH, Lumley JSP (2008). EMQs for medical students, Vols 1 & 2, 1st edition. Pastest, Knutsford, 2001, and 2nd edition 2008